Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Total Non-current Liabilities
All obligations due after more than one year.
Upstream Bio, Inc.NASDAQ: UPB
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 60.7% from a year ago
Total non-current liabilities stood at $390K at the end of Q1 FY2026, down 60.7% from a year earlier and down 29.0% from the prior quarter. Over 3 fiscal years it compounded at -83.4% a year.
Context
- Total non-current liabilities amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -60.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 549K USD
- Year-over-year change
- -51.4%
- 3-year CAGR
- -83.4%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 549K | -51.4% |
| FY2024 | 2024-12-31 | 1.13M | -99.5% |
| FY2023 | 2023-12-31 | 233.81M | +95.2% |
| FY2022 | 2022-12-31 | 119.78M | — |
Total Non-current Liabilities vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -60.7% is the lowest of 10, against a peer median of -10.7%.
- Total non-current liabilities amounts to 0.1% of total assets for UPB, versus a peer median of 3.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $845.46M USD | -10.7% | +24.9% | 81.0% | |
| Mar 2026 | $350.69M USD | +110528.4% | -31.1% | 46.9% | |
| Mar 2026 | $344.87M USD | +4.2% | +681.8% | 73.0% | |
| Mar 2026 | $61.4M USD | -34.4% | -24.9% | 8.1% | |
| Jun 2026 | $26.64M USD | -13.1% | -30.6% | 2.8% | |
| Mar 2026 | $21.98M USD | -24.6% | -47.7% | 3.8% | |
| Sep 2026 | $8.05M USD | +149.2% | -14.5% | 0.7% | |
| Sep 2026 | $4.01M USD | -19.0% | +3.5% | 0.5% | |
| Sep 2026 | €430.28K EUR | -2.4% | +32.2% | 0.1% | |
UPBUpstream Bio, Inc. | Mar 2026 | $390K USD | -60.7% | -83.4% | 0.1% |
| Peer median (excluding UPB) | — | -10.7% | -14.5% | 3.8% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.